Kymera Therapeutics (KYMR) Capital Expenditures Growth (3y) (2022 - 2026)
Kymera Therapeutics (KYMR) Capital Expenditures Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Kymera Therapeutics | 10.80 Bn | 10.15 Bn | - | -52.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.34% |
| Dec 31, 2025 | 81.44% |
| Sep 30, 2025 | -47.43% |
| Jun 30, 2025 | -1.85% |
| Mar 31, 2025 | -1.05% |
| Dec 31, 2024 | 1.47% |
| Sep 30, 2024 | -37.82% |
| Jun 30, 2024 | 95.66% |
| Mar 31, 2024 | 256.04% |
| Dec 31, 2023 | 50.79% |
| Sep 30, 2023 | -101.11% |
| Jun 30, 2023 | 40.83% |
| Mar 31, 2023 | 42.17% |
| Dec 31, 2022 | -110.76% |